nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—ALB—acquired immunodeficiency syndrome	0.157	1	CbGaD
Vandetanib—ABCC1—Amprenavir—acquired immunodeficiency syndrome	0.0495	0.108	CbGbCtD
Vandetanib—ABCC1—Indinavir—acquired immunodeficiency syndrome	0.0428	0.0934	CbGbCtD
Vandetanib—ORM1—Saquinavir—acquired immunodeficiency syndrome	0.0412	0.0899	CbGbCtD
Vandetanib—ABCC1—Saquinavir—acquired immunodeficiency syndrome	0.0375	0.082	CbGbCtD
Vandetanib—ABCC1—Ritonavir—acquired immunodeficiency syndrome	0.0375	0.082	CbGbCtD
Vandetanib—ABCC1—Lamivudine—acquired immunodeficiency syndrome	0.0278	0.0608	CbGbCtD
Vandetanib—ABCG2—Nelfinavir—acquired immunodeficiency syndrome	0.0278	0.0607	CbGbCtD
Vandetanib—ABCG2—Saquinavir—acquired immunodeficiency syndrome	0.0251	0.0549	CbGbCtD
Vandetanib—ABCG2—Ritonavir—acquired immunodeficiency syndrome	0.0251	0.0549	CbGbCtD
Vandetanib—ABCG2—Zidovudine—acquired immunodeficiency syndrome	0.0241	0.0526	CbGbCtD
Vandetanib—ABCG2—Lamivudine—acquired immunodeficiency syndrome	0.0186	0.0407	CbGbCtD
Vandetanib—ALB—Saquinavir—acquired immunodeficiency syndrome	0.0173	0.0378	CbGbCtD
Vandetanib—ALB—Zidovudine—acquired immunodeficiency syndrome	0.0166	0.0363	CbGbCtD
Vandetanib—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00842	0.0184	CbGbCtD
Vandetanib—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00792	0.0173	CbGbCtD
Vandetanib—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00792	0.0173	CbGbCtD
Vandetanib—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00716	0.0156	CbGbCtD
Vandetanib—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00716	0.0156	CbGbCtD
Vandetanib—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00618	0.0135	CbGbCtD
Vandetanib—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.006	0.0131	CbGbCtD
Vandetanib—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00543	0.0119	CbGbCtD
Vandetanib—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00543	0.0119	CbGbCtD
Vandetanib—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0052	0.0114	CbGbCtD
Vandetanib—Erlotinib—ALB—acquired immunodeficiency syndrome	0.000469	0.615	CrCbGaD
Vandetanib—FLT3—lung—acquired immunodeficiency syndrome	0.000396	0.00347	CbGeAlD
Vandetanib—RIPK2—bone marrow—acquired immunodeficiency syndrome	0.000395	0.00346	CbGeAlD
Vandetanib—VEGFA—bone marrow—acquired immunodeficiency syndrome	0.000394	0.00345	CbGeAlD
Vandetanib—RIPK2—spinal cord—acquired immunodeficiency syndrome	0.000393	0.00345	CbGeAlD
Vandetanib—VEGFA—spinal cord—acquired immunodeficiency syndrome	0.000392	0.00344	CbGeAlD
Vandetanib—MKNK1—lymphoid tissue—acquired immunodeficiency syndrome	0.00039	0.00342	CbGeAlD
Vandetanib—STK35—lung—acquired immunodeficiency syndrome	0.000388	0.0034	CbGeAlD
Vandetanib—IRAK4—bone marrow—acquired immunodeficiency syndrome	0.000385	0.00338	CbGeAlD
Vandetanib—MKNK1—digestive system—acquired immunodeficiency syndrome	0.000385	0.00337	CbGeAlD
Vandetanib—FGR—lymphoid tissue—acquired immunodeficiency syndrome	0.000385	0.00337	CbGeAlD
Vandetanib—RET—lymphoid tissue—acquired immunodeficiency syndrome	0.000385	0.00337	CbGeAlD
Vandetanib—SRC—skin of body—acquired immunodeficiency syndrome	0.000385	0.00337	CbGeAlD
Vandetanib—IRAK4—spinal cord—acquired immunodeficiency syndrome	0.000384	0.00337	CbGeAlD
Vandetanib—AXL—lymphoid tissue—acquired immunodeficiency syndrome	0.000383	0.00336	CbGeAlD
Vandetanib—FGR—digestive system—acquired immunodeficiency syndrome	0.00038	0.00333	CbGeAlD
Vandetanib—RET—digestive system—acquired immunodeficiency syndrome	0.00038	0.00333	CbGeAlD
Vandetanib—RIPK2—vagina—acquired immunodeficiency syndrome	0.000378	0.00332	CbGeAlD
Vandetanib—ABL2—lung—acquired immunodeficiency syndrome	0.000378	0.00331	CbGeAlD
Vandetanib—VEGFA—vagina—acquired immunodeficiency syndrome	0.000377	0.00331	CbGeAlD
Vandetanib—ERBB3—spinal cord—acquired immunodeficiency syndrome	0.000376	0.0033	CbGeAlD
Vandetanib—FMO1—vagina—acquired immunodeficiency syndrome	0.000375	0.00329	CbGeAlD
Vandetanib—IRAK4—vagina—acquired immunodeficiency syndrome	0.000369	0.00324	CbGeAlD
Vandetanib—EGFR—lung—acquired immunodeficiency syndrome	0.000369	0.00323	CbGeAlD
Vandetanib—MKNK1—blood—acquired immunodeficiency syndrome	0.000367	0.00321	CbGeAlD
Vandetanib—FGR—blood—acquired immunodeficiency syndrome	0.000362	0.00318	CbGeAlD
Vandetanib—RET—blood—acquired immunodeficiency syndrome	0.000362	0.00318	CbGeAlD
Vandetanib—LCK—blood—acquired immunodeficiency syndrome	0.000362	0.00318	CbGeAlD
Vandetanib—FLT4—lung—acquired immunodeficiency syndrome	0.00036	0.00315	CbGeAlD
Vandetanib—STK35—nervous system—acquired immunodeficiency syndrome	0.000359	0.00315	CbGeAlD
Vandetanib—FYN—lymphoid tissue—acquired immunodeficiency syndrome	0.000359	0.00315	CbGeAlD
Vandetanib—RIPK2—lung—acquired immunodeficiency syndrome	0.000358	0.00314	CbGeAlD
Vandetanib—VEGFA—lung—acquired immunodeficiency syndrome	0.000357	0.00313	CbGeAlD
Vandetanib—EPHA6—brain—acquired immunodeficiency syndrome	0.000355	0.00311	CbGeAlD
Vandetanib—FMO1—lung—acquired immunodeficiency syndrome	0.000355	0.00311	CbGeAlD
Vandetanib—MKNK1—bone marrow—acquired immunodeficiency syndrome	0.000355	0.00311	CbGeAlD
Vandetanib—FYN—digestive system—acquired immunodeficiency syndrome	0.000354	0.00311	CbGeAlD
Vandetanib—MKNK1—spinal cord—acquired immunodeficiency syndrome	0.000353	0.0031	CbGeAlD
Vandetanib—PLK4—brain—acquired immunodeficiency syndrome	0.000351	0.00308	CbGeAlD
Vandetanib—TEK—lymphoid tissue—acquired immunodeficiency syndrome	0.00035	0.00307	CbGeAlD
Vandetanib—MAP4K5—lymphoid tissue—acquired immunodeficiency syndrome	0.00035	0.00307	CbGeAlD
Vandetanib—LCK—bone marrow—acquired immunodeficiency syndrome	0.00035	0.00307	CbGeAlD
Vandetanib—FGR—bone marrow—acquired immunodeficiency syndrome	0.00035	0.00307	CbGeAlD
Vandetanib—IRAK4—lung—acquired immunodeficiency syndrome	0.000349	0.00306	CbGeAlD
Vandetanib—RET—spinal cord—acquired immunodeficiency syndrome	0.000349	0.00306	CbGeAlD
Vandetanib—AXL—spinal cord—acquired immunodeficiency syndrome	0.000347	0.00305	CbGeAlD
Vandetanib—SLK—blood—acquired immunodeficiency syndrome	0.000347	0.00304	CbGeAlD
Vandetanib—STK35—central nervous system—acquired immunodeficiency syndrome	0.000346	0.00303	CbGeAlD
Vandetanib—ERBB3—lung—acquired immunodeficiency syndrome	0.000342	0.003	CbGeAlD
Vandetanib—MKNK1—vagina—acquired immunodeficiency syndrome	0.00034	0.00298	CbGeAlD
Vandetanib—PLK4—lymph node—acquired immunodeficiency syndrome	0.000339	0.00297	CbGeAlD
Vandetanib—FYN—blood—acquired immunodeficiency syndrome	0.000338	0.00296	CbGeAlD
Vandetanib—SLK—bone marrow—acquired immunodeficiency syndrome	0.000336	0.00295	CbGeAlD
Vandetanib—LCK—vagina—acquired immunodeficiency syndrome	0.000336	0.00294	CbGeAlD
Vandetanib—FGR—vagina—acquired immunodeficiency syndrome	0.000336	0.00294	CbGeAlD
Vandetanib—SLK—spinal cord—acquired immunodeficiency syndrome	0.000334	0.00293	CbGeAlD
Vandetanib—AXL—vagina—acquired immunodeficiency syndrome	0.000334	0.00293	CbGeAlD
Vandetanib—TEK—blood—acquired immunodeficiency syndrome	0.00033	0.00289	CbGeAlD
Vandetanib—MAP4K5—blood—acquired immunodeficiency syndrome	0.00033	0.00289	CbGeAlD
Vandetanib—TYRO3—brain—acquired immunodeficiency syndrome	0.00033	0.00289	CbGeAlD
Vandetanib—EPHA5—brain—acquired immunodeficiency syndrome	0.00033	0.00289	CbGeAlD
Vandetanib—FMO1—nervous system—acquired immunodeficiency syndrome	0.000328	0.00288	CbGeAlD
Vandetanib—LYN—brain—acquired immunodeficiency syndrome	0.000328	0.00287	CbGeAlD
Vandetanib—FYN—bone marrow—acquired immunodeficiency syndrome	0.000327	0.00286	CbGeAlD
Vandetanib—FYN—spinal cord—acquired immunodeficiency syndrome	0.000325	0.00285	CbGeAlD
Vandetanib—FMO3—vagina—acquired immunodeficiency syndrome	0.000324	0.00284	CbGeAlD
Vandetanib—YES1—lymphoid tissue—acquired immunodeficiency syndrome	0.000324	0.00284	CbGeAlD
Vandetanib—IRAK4—nervous system—acquired immunodeficiency syndrome	0.000323	0.00284	CbGeAlD
Vandetanib—BMPR1B—brain—acquired immunodeficiency syndrome	0.000323	0.00283	CbGeAlD
Vandetanib—MAP3K19—brain—acquired immunodeficiency syndrome	0.000323	0.00283	CbGeAlD
Vandetanib—SLK—vagina—acquired immunodeficiency syndrome	0.000322	0.00282	CbGeAlD
Vandetanib—MKNK1—lung—acquired immunodeficiency syndrome	0.000321	0.00282	CbGeAlD
Vandetanib—STK10—lymphoid tissue—acquired immunodeficiency syndrome	0.000321	0.00281	CbGeAlD
Vandetanib—YES1—digestive system—acquired immunodeficiency syndrome	0.00032	0.0028	CbGeAlD
Vandetanib—MAP4K5—bone marrow—acquired immunodeficiency syndrome	0.000319	0.0028	CbGeAlD
Vandetanib—MAP4K5—spinal cord—acquired immunodeficiency syndrome	0.000318	0.00279	CbGeAlD
Vandetanib—TEK—spinal cord—acquired immunodeficiency syndrome	0.000318	0.00279	CbGeAlD
Vandetanib—FGR—lung—acquired immunodeficiency syndrome	0.000317	0.00278	CbGeAlD
Vandetanib—LCK—lung—acquired immunodeficiency syndrome	0.000317	0.00278	CbGeAlD
Vandetanib—ERBB3—nervous system—acquired immunodeficiency syndrome	0.000317	0.00278	CbGeAlD
Vandetanib—STK10—digestive system—acquired immunodeficiency syndrome	0.000317	0.00278	CbGeAlD
Vandetanib—FMO1—central nervous system—acquired immunodeficiency syndrome	0.000316	0.00277	CbGeAlD
Vandetanib—AXL—lung—acquired immunodeficiency syndrome	0.000316	0.00277	CbGeAlD
Vandetanib—EPHB6—blood—acquired immunodeficiency syndrome	0.000315	0.00276	CbGeAlD
Vandetanib—FYN—vagina—acquired immunodeficiency syndrome	0.000313	0.00274	CbGeAlD
Vandetanib—BMPR1B—lymph node—acquired immunodeficiency syndrome	0.000312	0.00274	CbGeAlD
Vandetanib—SRC—lymphoid tissue—acquired immunodeficiency syndrome	0.000311	0.00273	CbGeAlD
Vandetanib—IRAK4—central nervous system—acquired immunodeficiency syndrome	0.000311	0.00273	CbGeAlD
Vandetanib—ABL1—retina—acquired immunodeficiency syndrome	0.000311	0.00273	CbGeAlD
Vandetanib—SRC—digestive system—acquired immunodeficiency syndrome	0.000308	0.0027	CbGeAlD
Vandetanib—FMO3—lung—acquired immunodeficiency syndrome	0.000307	0.00269	CbGeAlD
Vandetanib—PDGFRB—skin of body—acquired immunodeficiency syndrome	0.000306	0.00269	CbGeAlD
Vandetanib—MAP4K5—vagina—acquired immunodeficiency syndrome	0.000306	0.00268	CbGeAlD
Vandetanib—ERBB3—central nervous system—acquired immunodeficiency syndrome	0.000305	0.00268	CbGeAlD
Vandetanib—YES1—blood—acquired immunodeficiency syndrome	0.000305	0.00267	CbGeAlD
Vandetanib—SLK—lung—acquired immunodeficiency syndrome	0.000304	0.00267	CbGeAlD
Vandetanib—EPHB6—spinal cord—acquired immunodeficiency syndrome	0.000304	0.00266	CbGeAlD
Vandetanib—STK10—blood—acquired immunodeficiency syndrome	0.000302	0.00265	CbGeAlD
Vandetanib—MKNK1—nervous system—acquired immunodeficiency syndrome	0.000298	0.00261	CbGeAlD
Vandetanib—FYN—lung—acquired immunodeficiency syndrome	0.000296	0.00259	CbGeAlD
Vandetanib—YES1—bone marrow—acquired immunodeficiency syndrome	0.000295	0.00258	CbGeAlD
Vandetanib—FGR—nervous system—acquired immunodeficiency syndrome	0.000294	0.00258	CbGeAlD
Vandetanib—RET—nervous system—acquired immunodeficiency syndrome	0.000294	0.00258	CbGeAlD
Vandetanib—Gefitinib—ALB—acquired immunodeficiency syndrome	0.000294	0.385	CrCbGaD
Vandetanib—YES1—spinal cord—acquired immunodeficiency syndrome	0.000293	0.00257	CbGeAlD
Vandetanib—SRC—blood—acquired immunodeficiency syndrome	0.000293	0.00257	CbGeAlD
Vandetanib—AXL—nervous system—acquired immunodeficiency syndrome	0.000293	0.00257	CbGeAlD
Vandetanib—EPHB6—vagina—acquired immunodeficiency syndrome	0.000292	0.00256	CbGeAlD
Vandetanib—STK10—bone marrow—acquired immunodeficiency syndrome	0.000292	0.00256	CbGeAlD
Vandetanib—MAP4K5—lung—acquired immunodeficiency syndrome	0.000289	0.00254	CbGeAlD
Vandetanib—TEK—lung—acquired immunodeficiency syndrome	0.000289	0.00254	CbGeAlD
Vandetanib—MKNK1—central nervous system—acquired immunodeficiency syndrome	0.000287	0.00251	CbGeAlD
Vandetanib—KDR—lymphoid tissue—acquired immunodeficiency syndrome	0.000286	0.00251	CbGeAlD
Vandetanib—FMO3—nervous system—acquired immunodeficiency syndrome	0.000284	0.00249	CbGeAlD
Vandetanib—FGR—central nervous system—acquired immunodeficiency syndrome	0.000283	0.00248	CbGeAlD
Vandetanib—RET—central nervous system—acquired immunodeficiency syndrome	0.000283	0.00248	CbGeAlD
Vandetanib—KDR—digestive system—acquired immunodeficiency syndrome	0.000283	0.00248	CbGeAlD
Vandetanib—YES1—vagina—acquired immunodeficiency syndrome	0.000282	0.00248	CbGeAlD
Vandetanib—SRC—spinal cord—acquired immunodeficiency syndrome	0.000282	0.00248	CbGeAlD
Vandetanib—AXL—central nervous system—acquired immunodeficiency syndrome	0.000282	0.00247	CbGeAlD
Vandetanib—STK10—vagina—acquired immunodeficiency syndrome	0.00028	0.00245	CbGeAlD
Vandetanib—EPHB6—lung—acquired immunodeficiency syndrome	0.000276	0.00242	CbGeAlD
Vandetanib—STK35—brain—acquired immunodeficiency syndrome	0.000275	0.00241	CbGeAlD
Vandetanib—FYN—nervous system—acquired immunodeficiency syndrome	0.000274	0.0024	CbGeAlD
Vandetanib—FMO3—central nervous system—acquired immunodeficiency syndrome	0.000273	0.0024	CbGeAlD
Vandetanib—ABL1—skin of body—acquired immunodeficiency syndrome	0.000273	0.00239	CbGeAlD
Vandetanib—FLT3—lymph node—acquired immunodeficiency syndrome	0.000271	0.00237	CbGeAlD
Vandetanib—MAP2K5—blood—acquired immunodeficiency syndrome	0.00027	0.00236	CbGeAlD
Vandetanib—KDR—blood—acquired immunodeficiency syndrome	0.00027	0.00236	CbGeAlD
Vandetanib—MAP4K5—nervous system—acquired immunodeficiency syndrome	0.000268	0.00235	CbGeAlD
Vandetanib—TEK—nervous system—acquired immunodeficiency syndrome	0.000268	0.00235	CbGeAlD
Vandetanib—ABL2—brain—acquired immunodeficiency syndrome	0.000268	0.00235	CbGeAlD
Vandetanib—YES1—lung—acquired immunodeficiency syndrome	0.000267	0.00234	CbGeAlD
Vandetanib—STK35—lymph node—acquired immunodeficiency syndrome	0.000265	0.00233	CbGeAlD
Vandetanib—STK10—lung—acquired immunodeficiency syndrome	0.000265	0.00232	CbGeAlD
Vandetanib—FYN—central nervous system—acquired immunodeficiency syndrome	0.000264	0.00231	CbGeAlD
Vandetanib—EGFR—brain—acquired immunodeficiency syndrome	0.000261	0.00229	CbGeAlD
Vandetanib—KDR—bone marrow—acquired immunodeficiency syndrome	0.000261	0.00229	CbGeAlD
Vandetanib—KDR—spinal cord—acquired immunodeficiency syndrome	0.00026	0.00228	CbGeAlD
Vandetanib—MAP2K5—spinal cord—acquired immunodeficiency syndrome	0.00026	0.00228	CbGeAlD
Vandetanib—ABL2—lymph node—acquired immunodeficiency syndrome	0.000258	0.00227	CbGeAlD
Vandetanib—TEK—central nervous system—acquired immunodeficiency syndrome	0.000258	0.00226	CbGeAlD
Vandetanib—MAP4K5—central nervous system—acquired immunodeficiency syndrome	0.000258	0.00226	CbGeAlD
Vandetanib—SRC—lung—acquired immunodeficiency syndrome	0.000257	0.00225	CbGeAlD
Vandetanib—EPHB6—nervous system—acquired immunodeficiency syndrome	0.000256	0.00224	CbGeAlD
Vandetanib—FLT4—brain—acquired immunodeficiency syndrome	0.000254	0.00223	CbGeAlD
Vandetanib—RIPK2—brain—acquired immunodeficiency syndrome	0.000253	0.00222	CbGeAlD
Vandetanib—VEGFA—brain—acquired immunodeficiency syndrome	0.000252	0.00221	CbGeAlD
Vandetanib—EGFR—lymph node—acquired immunodeficiency syndrome	0.000252	0.00221	CbGeAlD
Vandetanib—FMO1—brain—acquired immunodeficiency syndrome	0.000251	0.0022	CbGeAlD
Vandetanib—KDR—vagina—acquired immunodeficiency syndrome	0.00025	0.00219	CbGeAlD
Vandetanib—MAP2K5—vagina—acquired immunodeficiency syndrome	0.00025	0.00219	CbGeAlD
Vandetanib—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000249	0.00219	CbGeAlD
Vandetanib—PDGFRB—lymphoid tissue—acquired immunodeficiency syndrome	0.000248	0.00217	CbGeAlD
Vandetanib—YES1—nervous system—acquired immunodeficiency syndrome	0.000247	0.00217	CbGeAlD
Vandetanib—IRAK4—brain—acquired immunodeficiency syndrome	0.000247	0.00217	CbGeAlD
Vandetanib—EPHB6—central nervous system—acquired immunodeficiency syndrome	0.000246	0.00216	CbGeAlD
Vandetanib—FLT4—lymph node—acquired immunodeficiency syndrome	0.000246	0.00216	CbGeAlD
Vandetanib—STK10—nervous system—acquired immunodeficiency syndrome	0.000245	0.00215	CbGeAlD
Vandetanib—PDGFRB—digestive system—acquired immunodeficiency syndrome	0.000245	0.00215	CbGeAlD
Vandetanib—RIPK2—lymph node—acquired immunodeficiency syndrome	0.000245	0.00214	CbGeAlD
Vandetanib—VEGFA—lymph node—acquired immunodeficiency syndrome	0.000244	0.00214	CbGeAlD
Vandetanib—FMO1—lymph node—acquired immunodeficiency syndrome	0.000243	0.00213	CbGeAlD
Vandetanib—ERBB3—brain—acquired immunodeficiency syndrome	0.000242	0.00212	CbGeAlD
Vandetanib—IRAK4—lymph node—acquired immunodeficiency syndrome	0.000239	0.00209	CbGeAlD
Vandetanib—YES1—central nervous system—acquired immunodeficiency syndrome	0.000238	0.00209	CbGeAlD
Vandetanib—SRC—nervous system—acquired immunodeficiency syndrome	0.000238	0.00209	CbGeAlD
Vandetanib—KDR—lung—acquired immunodeficiency syndrome	0.000236	0.00207	CbGeAlD
Vandetanib—MAP2K5—lung—acquired immunodeficiency syndrome	0.000236	0.00207	CbGeAlD
Vandetanib—STK10—central nervous system—acquired immunodeficiency syndrome	0.000236	0.00207	CbGeAlD
Vandetanib—ERBB3—lymph node—acquired immunodeficiency syndrome	0.000234	0.00205	CbGeAlD
Vandetanib—PDGFRB—blood—acquired immunodeficiency syndrome	0.000233	0.00205	CbGeAlD
Vandetanib—SRC—central nervous system—acquired immunodeficiency syndrome	0.000229	0.00201	CbGeAlD
Vandetanib—MKNK1—brain—acquired immunodeficiency syndrome	0.000227	0.00199	CbGeAlD
Vandetanib—PDGFRB—bone marrow—acquired immunodeficiency syndrome	0.000226	0.00198	CbGeAlD
Vandetanib—PDGFRB—spinal cord—acquired immunodeficiency syndrome	0.000225	0.00197	CbGeAlD
Vandetanib—FGR—brain—acquired immunodeficiency syndrome	0.000225	0.00197	CbGeAlD
Vandetanib—RET—brain—acquired immunodeficiency syndrome	0.000225	0.00197	CbGeAlD
Vandetanib—AXL—brain—acquired immunodeficiency syndrome	0.000224	0.00196	CbGeAlD
Vandetanib—ABL1—lymphoid tissue—acquired immunodeficiency syndrome	0.000221	0.00194	CbGeAlD
Vandetanib—MKNK1—lymph node—acquired immunodeficiency syndrome	0.00022	0.00193	CbGeAlD
Vandetanib—ORM1—blood—acquired immunodeficiency syndrome	0.000219	0.00192	CbGeAlD
Vandetanib—KDR—nervous system—acquired immunodeficiency syndrome	0.000219	0.00192	CbGeAlD
Vandetanib—MAP2K5—nervous system—acquired immunodeficiency syndrome	0.000219	0.00192	CbGeAlD
Vandetanib—ABL1—digestive system—acquired immunodeficiency syndrome	0.000218	0.00191	CbGeAlD
Vandetanib—RET—lymph node—acquired immunodeficiency syndrome	0.000217	0.0019	CbGeAlD
Vandetanib—LCK—lymph node—acquired immunodeficiency syndrome	0.000217	0.0019	CbGeAlD
Vandetanib—FGR—lymph node—acquired immunodeficiency syndrome	0.000217	0.0019	CbGeAlD
Vandetanib—FMO3—brain—acquired immunodeficiency syndrome	0.000217	0.0019	CbGeAlD
Vandetanib—PDGFRB—vagina—acquired immunodeficiency syndrome	0.000216	0.0019	CbGeAlD
Vandetanib—AXL—lymph node—acquired immunodeficiency syndrome	0.000216	0.0019	CbGeAlD
Vandetanib—SLK—brain—acquired immunodeficiency syndrome	0.000215	0.00189	CbGeAlD
Vandetanib—ORM1—bone marrow—acquired immunodeficiency syndrome	0.000212	0.00186	CbGeAlD
Vandetanib—ORM1—spinal cord—acquired immunodeficiency syndrome	0.000211	0.00185	CbGeAlD
Vandetanib—MAP2K5—central nervous system—acquired immunodeficiency syndrome	0.000211	0.00185	CbGeAlD
Vandetanib—KDR—central nervous system—acquired immunodeficiency syndrome	0.000211	0.00185	CbGeAlD
Vandetanib—FMO3—lymph node—acquired immunodeficiency syndrome	0.00021	0.00184	CbGeAlD
Vandetanib—FYN—brain—acquired immunodeficiency syndrome	0.000209	0.00184	CbGeAlD
Vandetanib—SLK—lymph node—acquired immunodeficiency syndrome	0.000208	0.00183	CbGeAlD
Vandetanib—ABL1—blood—acquired immunodeficiency syndrome	0.000208	0.00182	CbGeAlD
Vandetanib—MAP4K5—brain—acquired immunodeficiency syndrome	0.000205	0.00179	CbGeAlD
Vandetanib—TEK—brain—acquired immunodeficiency syndrome	0.000205	0.00179	CbGeAlD
Vandetanib—PDGFRB—lung—acquired immunodeficiency syndrome	0.000205	0.00179	CbGeAlD
Vandetanib—FYN—lymph node—acquired immunodeficiency syndrome	0.000202	0.00177	CbGeAlD
Vandetanib—ABL1—bone marrow—acquired immunodeficiency syndrome	0.000201	0.00176	CbGeAlD
Vandetanib—ABL1—spinal cord—acquired immunodeficiency syndrome	0.0002	0.00176	CbGeAlD
Vandetanib—MAP4K5—lymph node—acquired immunodeficiency syndrome	0.000198	0.00173	CbGeAlD
Vandetanib—TEK—lymph node—acquired immunodeficiency syndrome	0.000198	0.00173	CbGeAlD
Vandetanib—EPHB6—brain—acquired immunodeficiency syndrome	0.000196	0.00172	CbGeAlD
Vandetanib—ABL1—vagina—acquired immunodeficiency syndrome	0.000193	0.00169	CbGeAlD
Vandetanib—ORM1—lung—acquired immunodeficiency syndrome	0.000192	0.00168	CbGeAlD
Vandetanib—PDGFRB—nervous system—acquired immunodeficiency syndrome	0.000189	0.00166	CbGeAlD
Vandetanib—YES1—brain—acquired immunodeficiency syndrome	0.000189	0.00166	CbGeAlD
Vandetanib—EPHB6—lymph node—acquired immunodeficiency syndrome	0.000189	0.00166	CbGeAlD
Vandetanib—STK10—brain—acquired immunodeficiency syndrome	0.000187	0.00164	CbGeAlD
Vandetanib—YES1—lymph node—acquired immunodeficiency syndrome	0.000183	0.0016	CbGeAlD
Vandetanib—PDGFRB—central nervous system—acquired immunodeficiency syndrome	0.000182	0.0016	CbGeAlD
Vandetanib—ABL1—lung—acquired immunodeficiency syndrome	0.000182	0.0016	CbGeAlD
Vandetanib—SRC—brain—acquired immunodeficiency syndrome	0.000182	0.00159	CbGeAlD
Vandetanib—STK10—lymph node—acquired immunodeficiency syndrome	0.000181	0.00159	CbGeAlD
Vandetanib—ORM1—nervous system—acquired immunodeficiency syndrome	0.000178	0.00156	CbGeAlD
Vandetanib—SRC—lymph node—acquired immunodeficiency syndrome	0.000176	0.00154	CbGeAlD
Vandetanib—ORM1—central nervous system—acquired immunodeficiency syndrome	0.000171	0.0015	CbGeAlD
Vandetanib—ABL1—nervous system—acquired immunodeficiency syndrome	0.000169	0.00148	CbGeAlD
Vandetanib—MAP2K5—brain—acquired immunodeficiency syndrome	0.000167	0.00147	CbGeAlD
Vandetanib—KDR—brain—acquired immunodeficiency syndrome	0.000167	0.00147	CbGeAlD
Vandetanib—ABL1—central nervous system—acquired immunodeficiency syndrome	0.000163	0.00143	CbGeAlD
Vandetanib—KDR—lymph node—acquired immunodeficiency syndrome	0.000162	0.00142	CbGeAlD
Vandetanib—MAP2K5—lymph node—acquired immunodeficiency syndrome	0.000162	0.00142	CbGeAlD
Vandetanib—ABCC1—blood—acquired immunodeficiency syndrome	0.000158	0.00139	CbGeAlD
Vandetanib—ABCC1—vagina—acquired immunodeficiency syndrome	0.000147	0.00129	CbGeAlD
Vandetanib—PDGFRB—brain—acquired immunodeficiency syndrome	0.000145	0.00127	CbGeAlD
Vandetanib—PDGFRB—lymph node—acquired immunodeficiency syndrome	0.00014	0.00123	CbGeAlD
Vandetanib—ABCC1—lung—acquired immunodeficiency syndrome	0.000139	0.00122	CbGeAlD
Vandetanib—ORM1—lymph node—acquired immunodeficiency syndrome	0.000131	0.00115	CbGeAlD
Vandetanib—ABCG2—blood—acquired immunodeficiency syndrome	0.000131	0.00115	CbGeAlD
Vandetanib—ABL1—brain—acquired immunodeficiency syndrome	0.000129	0.00113	CbGeAlD
Vandetanib—ABCG2—bone marrow—acquired immunodeficiency syndrome	0.000127	0.00111	CbGeAlD
Vandetanib—ABCG2—spinal cord—acquired immunodeficiency syndrome	0.000126	0.00111	CbGeAlD
Vandetanib—ABL1—lymph node—acquired immunodeficiency syndrome	0.000125	0.00109	CbGeAlD
Vandetanib—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.000124	0.000644	CcSEcCtD
Vandetanib—Alopecia—Lamivudine—acquired immunodeficiency syndrome	0.000124	0.000643	CcSEcCtD
Vandetanib—Muscle spasms—Saquinavir—acquired immunodeficiency syndrome	0.000123	0.000638	CcSEcCtD
Vandetanib—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.000123	0.000637	CcSEcCtD
Vandetanib—Chest pain—Delavirdine—acquired immunodeficiency syndrome	0.000123	0.000635	CcSEcCtD
Vandetanib—Arthralgia—Delavirdine—acquired immunodeficiency syndrome	0.000123	0.000635	CcSEcCtD
Vandetanib—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	0.000122	0.000633	CcSEcCtD
Vandetanib—Anxiety—Delavirdine—acquired immunodeficiency syndrome	0.000122	0.000632	CcSEcCtD
Vandetanib—ABCG2—vagina—acquired immunodeficiency syndrome	0.000122	0.00107	CbGeAlD
Vandetanib—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	0.000121	0.000629	CcSEcCtD
Vandetanib—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000121	0.000625	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000121	0.000625	CcSEcCtD
Vandetanib—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.00012	0.000624	CcSEcCtD
Vandetanib—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.00012	0.000624	CcSEcCtD
Vandetanib—Thrombocytopenia—Efavirenz—acquired immunodeficiency syndrome	0.00012	0.000623	CcSEcCtD
Vandetanib—Tremor—Saquinavir—acquired immunodeficiency syndrome	0.00012	0.000622	CcSEcCtD
Vandetanib—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.00012	0.000621	CcSEcCtD
Vandetanib—Dysgeusia—Lamivudine—acquired immunodeficiency syndrome	0.00012	0.00062	CcSEcCtD
Vandetanib—Pain—Zidovudine—acquired immunodeficiency syndrome	0.00012	0.000619	CcSEcCtD
Vandetanib—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.00012	0.000619	CcSEcCtD
Vandetanib—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000119	0.000619	CcSEcCtD
Vandetanib—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000119	0.000618	CcSEcCtD
Vandetanib—ALB—brain—acquired immunodeficiency syndrome	0.000119	0.00104	CbGeAlD
Vandetanib—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.000118	0.000613	CcSEcCtD
Vandetanib—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000118	0.00061	CcSEcCtD
Vandetanib—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000118	0.00061	CcSEcCtD
Vandetanib—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000118	0.000609	CcSEcCtD
Vandetanib—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.000118	0.000609	CcSEcCtD
Vandetanib—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000117	0.000608	CcSEcCtD
Vandetanib—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.000117	0.000606	CcSEcCtD
Vandetanib—Rash—Didanosine—acquired immunodeficiency syndrome	0.000117	0.000605	CcSEcCtD
Vandetanib—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000117	0.000604	CcSEcCtD
Vandetanib—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.000117	0.000604	CcSEcCtD
Vandetanib—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000117	0.000604	CcSEcCtD
Vandetanib—Cough—Ritonavir—acquired immunodeficiency syndrome	0.000116	0.000602	CcSEcCtD
Vandetanib—Headache—Didanosine—acquired immunodeficiency syndrome	0.000116	0.000601	CcSEcCtD
Vandetanib—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000116	0.0006	CcSEcCtD
Vandetanib—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000116	0.000599	CcSEcCtD
Vandetanib—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000115	0.000597	CcSEcCtD
Vandetanib—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.000115	0.000597	CcSEcCtD
Vandetanib—ALB—lymph node—acquired immunodeficiency syndrome	0.000115	0.00101	CbGeAlD
Vandetanib—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.000115	0.000596	CcSEcCtD
Vandetanib—ABCG2—lung—acquired immunodeficiency syndrome	0.000115	0.00101	CbGeAlD
Vandetanib—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000115	0.000595	CcSEcCtD
Vandetanib—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000115	0.000593	CcSEcCtD
Vandetanib—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000114	0.000592	CcSEcCtD
Vandetanib—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000114	0.000592	CcSEcCtD
Vandetanib—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000114	0.000591	CcSEcCtD
Vandetanib—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000114	0.000591	CcSEcCtD
Vandetanib—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000114	0.00059	CcSEcCtD
Vandetanib—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000114	0.000589	CcSEcCtD
Vandetanib—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000114	0.000588	CcSEcCtD
Vandetanib—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.000113	0.000587	CcSEcCtD
Vandetanib—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000113	0.000587	CcSEcCtD
Vandetanib—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000113	0.000585	CcSEcCtD
Vandetanib—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000113	0.000585	CcSEcCtD
Vandetanib—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000113	0.000583	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000113	0.000583	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000112	0.000581	CcSEcCtD
Vandetanib—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000112	0.00058	CcSEcCtD
Vandetanib—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000112	0.00058	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000112	0.000579	CcSEcCtD
Vandetanib—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000112	0.000579	CcSEcCtD
Vandetanib—Pain—Indinavir—acquired immunodeficiency syndrome	0.000111	0.000576	CcSEcCtD
Vandetanib—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000111	0.000576	CcSEcCtD
Vandetanib—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000111	0.000575	CcSEcCtD
Vandetanib—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000111	0.000575	CcSEcCtD
Vandetanib—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000111	0.000574	CcSEcCtD
Vandetanib—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000111	0.000573	CcSEcCtD
Vandetanib—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.00011	0.000572	CcSEcCtD
Vandetanib—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.00011	0.000572	CcSEcCtD
Vandetanib—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.00011	0.000571	CcSEcCtD
Vandetanib—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.00011	0.000571	CcSEcCtD
Vandetanib—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.00011	0.00057	CcSEcCtD
Vandetanib—Nausea—Didanosine—acquired immunodeficiency syndrome	0.00011	0.00057	CcSEcCtD
Vandetanib—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000109	0.000567	CcSEcCtD
Vandetanib—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.000109	0.000565	CcSEcCtD
Vandetanib—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000109	0.000565	CcSEcCtD
Vandetanib—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000109	0.000563	CcSEcCtD
Vandetanib—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000109	0.000563	CcSEcCtD
Vandetanib—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000108	0.000561	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000108	0.000561	CcSEcCtD
Vandetanib—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000108	0.00056	CcSEcCtD
Vandetanib—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000107	0.000556	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000107	0.000554	CcSEcCtD
Vandetanib—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000107	0.000553	CcSEcCtD
Vandetanib—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000107	0.000552	CcSEcCtD
Vandetanib—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000107	0.000552	CcSEcCtD
Vandetanib—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000107	0.000552	CcSEcCtD
Vandetanib—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000107	0.000552	CcSEcCtD
Vandetanib—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.000106	0.000551	CcSEcCtD
Vandetanib—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000106	0.000551	CcSEcCtD
Vandetanib—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000106	0.00055	CcSEcCtD
Vandetanib—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000106	0.00055	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000106	0.000549	CcSEcCtD
Vandetanib—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000106	0.000548	CcSEcCtD
Vandetanib—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000106	0.000548	CcSEcCtD
Vandetanib—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000106	0.000548	CcSEcCtD
Vandetanib—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000106	0.000546	CcSEcCtD
Vandetanib—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000105	0.000546	CcSEcCtD
Vandetanib—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000105	0.000544	CcSEcCtD
Vandetanib—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000105	0.000544	CcSEcCtD
Vandetanib—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000105	0.000544	CcSEcCtD
Vandetanib—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000105	0.000543	CcSEcCtD
Vandetanib—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000105	0.000542	CcSEcCtD
Vandetanib—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000105	0.000542	CcSEcCtD
Vandetanib—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000105	0.000541	CcSEcCtD
Vandetanib—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000104	0.00054	CcSEcCtD
Vandetanib—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000104	0.000539	CcSEcCtD
Vandetanib—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000104	0.000539	CcSEcCtD
Vandetanib—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000104	0.000538	CcSEcCtD
Vandetanib—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000104	0.000537	CcSEcCtD
Vandetanib—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000103	0.000536	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000103	0.000535	CcSEcCtD
Vandetanib—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000103	0.000532	CcSEcCtD
Vandetanib—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000103	0.000532	CcSEcCtD
Vandetanib—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000103	0.000531	CcSEcCtD
Vandetanib—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000103	0.000531	CcSEcCtD
Vandetanib—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.000102	0.00053	CcSEcCtD
Vandetanib—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000102	0.000529	CcSEcCtD
Vandetanib—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000102	0.000529	CcSEcCtD
Vandetanib—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000102	0.000527	CcSEcCtD
Vandetanib—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000102	0.000527	CcSEcCtD
Vandetanib—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000102	0.000526	CcSEcCtD
Vandetanib—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000102	0.000526	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000101	0.000525	CcSEcCtD
Vandetanib—Rash—Stavudine—acquired immunodeficiency syndrome	0.000101	0.000525	CcSEcCtD
Vandetanib—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000101	0.000525	CcSEcCtD
Vandetanib—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000101	0.000524	CcSEcCtD
Vandetanib—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000101	0.000523	CcSEcCtD
Vandetanib—Headache—Stavudine—acquired immunodeficiency syndrome	0.000101	0.000522	CcSEcCtD
Vandetanib—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000101	0.000521	CcSEcCtD
Vandetanib—Pain—Delavirdine—acquired immunodeficiency syndrome	0.0001	0.00052	CcSEcCtD
Vandetanib—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.0001	0.00052	CcSEcCtD
Vandetanib—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.0001	0.00052	CcSEcCtD
Vandetanib—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.0001	0.000519	CcSEcCtD
Vandetanib—Rash—Abacavir—acquired immunodeficiency syndrome	9.99e-05	0.000517	CcSEcCtD
Vandetanib—Dermatitis—Abacavir—acquired immunodeficiency syndrome	9.98e-05	0.000517	CcSEcCtD
Vandetanib—Oedema—Lamivudine—acquired immunodeficiency syndrome	9.98e-05	0.000517	CcSEcCtD
Vandetanib—Headache—Abacavir—acquired immunodeficiency syndrome	9.92e-05	0.000514	CcSEcCtD
Vandetanib—Infection—Lamivudine—acquired immunodeficiency syndrome	9.91e-05	0.000513	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	9.9e-05	0.000513	CcSEcCtD
Vandetanib—Nausea—Nevirapine—acquired immunodeficiency syndrome	9.89e-05	0.000512	CcSEcCtD
Vandetanib—Pruritus—Zidovudine—acquired immunodeficiency syndrome	9.89e-05	0.000512	CcSEcCtD
Vandetanib—ABCC1—brain—acquired immunodeficiency syndrome	9.83e-05	0.000862	CbGeAlD
Vandetanib—Insomnia—Ritonavir—acquired immunodeficiency syndrome	9.83e-05	0.000509	CcSEcCtD
Vandetanib—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	9.78e-05	0.000507	CcSEcCtD
Vandetanib—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	9.77e-05	0.000506	CcSEcCtD
Vandetanib—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	9.76e-05	0.000505	CcSEcCtD
Vandetanib—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	9.71e-05	0.000503	CcSEcCtD
Vandetanib—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	9.71e-05	0.000503	CcSEcCtD
Vandetanib—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	9.69e-05	0.000502	CcSEcCtD
Vandetanib—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	9.69e-05	0.000502	CcSEcCtD
Vandetanib—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	9.61e-05	0.000497	CcSEcCtD
Vandetanib—CYP3A4—digestive system—acquired immunodeficiency syndrome	9.59e-05	0.000841	CbGeAlD
Vandetanib—Nausea—Nelfinavir—acquired immunodeficiency syndrome	9.58e-05	0.000496	CcSEcCtD
Vandetanib—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	9.56e-05	0.000495	CcSEcCtD
Vandetanib—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	9.56e-05	0.000495	CcSEcCtD
Vandetanib—Nausea—Stavudine—acquired immunodeficiency syndrome	9.55e-05	0.000495	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	9.53e-05	0.000493	CcSEcCtD
Vandetanib—ABCC1—lymph node—acquired immunodeficiency syndrome	9.5e-05	0.000833	CbGeAlD
Vandetanib—Insomnia—Saquinavir—acquired immunodeficiency syndrome	9.46e-05	0.00049	CcSEcCtD
Vandetanib—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	9.44e-05	0.000489	CcSEcCtD
Vandetanib—Nausea—Abacavir—acquired immunodeficiency syndrome	9.41e-05	0.000487	CcSEcCtD
Vandetanib—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	9.39e-05	0.000486	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	9.38e-05	0.000486	CcSEcCtD
Vandetanib—Fatigue—Ritonavir—acquired immunodeficiency syndrome	9.37e-05	0.000485	CcSEcCtD
Vandetanib—Asthenia—Indinavir—acquired immunodeficiency syndrome	9.32e-05	0.000483	CcSEcCtD
Vandetanib—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	9.32e-05	0.000483	CcSEcCtD
Vandetanib—Pain—Ritonavir—acquired immunodeficiency syndrome	9.29e-05	0.000481	CcSEcCtD
Vandetanib—Constipation—Ritonavir—acquired immunodeficiency syndrome	9.29e-05	0.000481	CcSEcCtD
Vandetanib—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	9.29e-05	0.000481	CcSEcCtD
Vandetanib—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	9.29e-05	0.000481	CcSEcCtD
Vandetanib—Dizziness—Zidovudine—acquired immunodeficiency syndrome	9.24e-05	0.000479	CcSEcCtD
Vandetanib—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	9.2e-05	0.000477	CcSEcCtD
Vandetanib—Pruritus—Indinavir—acquired immunodeficiency syndrome	9.19e-05	0.000476	CcSEcCtD
Vandetanib—CYP3A4—blood—acquired immunodeficiency syndrome	9.14e-05	0.000801	CbGeAlD
Vandetanib—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	9.09e-05	0.000471	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	9.09e-05	0.000471	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	9.03e-05	0.000467	CcSEcCtD
Vandetanib—Insomnia—Lamivudine—acquired immunodeficiency syndrome	9.02e-05	0.000467	CcSEcCtD
Vandetanib—Fatigue—Saquinavir—acquired immunodeficiency syndrome	9.02e-05	0.000467	CcSEcCtD
Vandetanib—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	8.96e-05	0.000464	CcSEcCtD
Vandetanib—Pain—Saquinavir—acquired immunodeficiency syndrome	8.94e-05	0.000463	CcSEcCtD
Vandetanib—Constipation—Saquinavir—acquired immunodeficiency syndrome	8.94e-05	0.000463	CcSEcCtD
Vandetanib—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	8.89e-05	0.000461	CcSEcCtD
Vandetanib—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	8.89e-05	0.00046	CcSEcCtD
Vandetanib—Vomiting—Zidovudine—acquired immunodeficiency syndrome	8.89e-05	0.00046	CcSEcCtD
Vandetanib—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	8.88e-05	0.00046	CcSEcCtD
Vandetanib—Rash—Zidovudine—acquired immunodeficiency syndrome	8.81e-05	0.000456	CcSEcCtD
Vandetanib—Asthenia—Efavirenz—acquired immunodeficiency syndrome	8.81e-05	0.000456	CcSEcCtD
Vandetanib—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	8.8e-05	0.000456	CcSEcCtD
Vandetanib—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	8.78e-05	0.000455	CcSEcCtD
Vandetanib—Headache—Zidovudine—acquired immunodeficiency syndrome	8.75e-05	0.000453	CcSEcCtD
Vandetanib—Pruritus—Efavirenz—acquired immunodeficiency syndrome	8.69e-05	0.00045	CcSEcCtD
Vandetanib—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	8.67e-05	0.000449	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	8.61e-05	0.000446	CcSEcCtD
Vandetanib—Fatigue—Lamivudine—acquired immunodeficiency syndrome	8.6e-05	0.000445	CcSEcCtD
Vandetanib—Dizziness—Indinavir—acquired immunodeficiency syndrome	8.59e-05	0.000445	CcSEcCtD
Vandetanib—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	8.59e-05	0.000445	CcSEcCtD
Vandetanib—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	8.59e-05	0.000445	CcSEcCtD
Vandetanib—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	8.55e-05	0.000443	CcSEcCtD
Vandetanib—Constipation—Lamivudine—acquired immunodeficiency syndrome	8.53e-05	0.000442	CcSEcCtD
Vandetanib—Pain—Lamivudine—acquired immunodeficiency syndrome	8.53e-05	0.000442	CcSEcCtD
Vandetanib—Asthenia—Delavirdine—acquired immunodeficiency syndrome	8.43e-05	0.000437	CcSEcCtD
Vandetanib—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	8.4e-05	0.000435	CcSEcCtD
Vandetanib—Pruritus—Delavirdine—acquired immunodeficiency syndrome	8.31e-05	0.00043	CcSEcCtD
Vandetanib—Nausea—Zidovudine—acquired immunodeficiency syndrome	8.3e-05	0.00043	CcSEcCtD
Vandetanib—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	8.27e-05	0.000428	CcSEcCtD
Vandetanib—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	8.27e-05	0.000428	CcSEcCtD
Vandetanib—Vomiting—Indinavir—acquired immunodeficiency syndrome	8.26e-05	0.000428	CcSEcCtD
Vandetanib—Rash—Indinavir—acquired immunodeficiency syndrome	8.19e-05	0.000424	CcSEcCtD
Vandetanib—Dermatitis—Indinavir—acquired immunodeficiency syndrome	8.19e-05	0.000424	CcSEcCtD
Vandetanib—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	8.16e-05	0.000422	CcSEcCtD
Vandetanib—Headache—Indinavir—acquired immunodeficiency syndrome	8.14e-05	0.000422	CcSEcCtD
Vandetanib—ABCG2—brain—acquired immunodeficiency syndrome	8.14e-05	0.000714	CbGeAlD
Vandetanib—Dizziness—Efavirenz—acquired immunodeficiency syndrome	8.12e-05	0.00042	CcSEcCtD
Vandetanib—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	8.04e-05	0.000416	CcSEcCtD
Vandetanib—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	7.89e-05	0.000408	CcSEcCtD
Vandetanib—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	7.89e-05	0.000408	CcSEcCtD
Vandetanib—ABCG2—lymph node—acquired immunodeficiency syndrome	7.86e-05	0.00069	CbGeAlD
Vandetanib—Vomiting—Efavirenz—acquired immunodeficiency syndrome	7.81e-05	0.000404	CcSEcCtD
Vandetanib—Asthenia—Ritonavir—acquired immunodeficiency syndrome	7.79e-05	0.000404	CcSEcCtD
Vandetanib—Dizziness—Delavirdine—acquired immunodeficiency syndrome	7.77e-05	0.000402	CcSEcCtD
Vandetanib—Rash—Efavirenz—acquired immunodeficiency syndrome	7.74e-05	0.000401	CcSEcCtD
Vandetanib—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	7.73e-05	0.000401	CcSEcCtD
Vandetanib—Nausea—Indinavir—acquired immunodeficiency syndrome	7.72e-05	0.0004	CcSEcCtD
Vandetanib—Headache—Efavirenz—acquired immunodeficiency syndrome	7.69e-05	0.000398	CcSEcCtD
Vandetanib—Pruritus—Ritonavir—acquired immunodeficiency syndrome	7.69e-05	0.000398	CcSEcCtD
Vandetanib—Asthenia—Saquinavir—acquired immunodeficiency syndrome	7.5e-05	0.000389	CcSEcCtD
Vandetanib—Vomiting—Delavirdine—acquired immunodeficiency syndrome	7.47e-05	0.000387	CcSEcCtD
Vandetanib—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	7.43e-05	0.000385	CcSEcCtD
Vandetanib—CYP3A4—nervous system—acquired immunodeficiency syndrome	7.42e-05	0.00065	CbGeAlD
Vandetanib—Rash—Delavirdine—acquired immunodeficiency syndrome	7.41e-05	0.000384	CcSEcCtD
Vandetanib—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	7.4e-05	0.000383	CcSEcCtD
Vandetanib—Pruritus—Saquinavir—acquired immunodeficiency syndrome	7.4e-05	0.000383	CcSEcCtD
Vandetanib—Headache—Delavirdine—acquired immunodeficiency syndrome	7.36e-05	0.000381	CcSEcCtD
Vandetanib—Nausea—Efavirenz—acquired immunodeficiency syndrome	7.29e-05	0.000378	CcSEcCtD
Vandetanib—Dizziness—Ritonavir—acquired immunodeficiency syndrome	7.18e-05	0.000372	CcSEcCtD
Vandetanib—Asthenia—Lamivudine—acquired immunodeficiency syndrome	7.16e-05	0.000371	CcSEcCtD
Vandetanib—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	7.15e-05	0.00037	CcSEcCtD
Vandetanib—CYP3A4—central nervous system—acquired immunodeficiency syndrome	7.14e-05	0.000626	CbGeAlD
Vandetanib—Pruritus—Lamivudine—acquired immunodeficiency syndrome	7.06e-05	0.000365	CcSEcCtD
Vandetanib—Nausea—Delavirdine—acquired immunodeficiency syndrome	6.98e-05	0.000361	CcSEcCtD
Vandetanib—Dizziness—Saquinavir—acquired immunodeficiency syndrome	6.91e-05	0.000358	CcSEcCtD
Vandetanib—Vomiting—Ritonavir—acquired immunodeficiency syndrome	6.91e-05	0.000358	CcSEcCtD
Vandetanib—Rash—Ritonavir—acquired immunodeficiency syndrome	6.85e-05	0.000355	CcSEcCtD
Vandetanib—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	6.84e-05	0.000354	CcSEcCtD
Vandetanib—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	6.83e-05	0.000353	CcSEcCtD
Vandetanib—Headache—Ritonavir—acquired immunodeficiency syndrome	6.81e-05	0.000352	CcSEcCtD
Vandetanib—Vomiting—Saquinavir—acquired immunodeficiency syndrome	6.65e-05	0.000344	CcSEcCtD
Vandetanib—Dizziness—Lamivudine—acquired immunodeficiency syndrome	6.6e-05	0.000342	CcSEcCtD
Vandetanib—Rash—Saquinavir—acquired immunodeficiency syndrome	6.59e-05	0.000341	CcSEcCtD
Vandetanib—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	6.59e-05	0.000341	CcSEcCtD
Vandetanib—Headache—Saquinavir—acquired immunodeficiency syndrome	6.55e-05	0.000339	CcSEcCtD
Vandetanib—Nausea—Ritonavir—acquired immunodeficiency syndrome	6.45e-05	0.000334	CcSEcCtD
Vandetanib—Vomiting—Lamivudine—acquired immunodeficiency syndrome	6.34e-05	0.000328	CcSEcCtD
Vandetanib—Rash—Lamivudine—acquired immunodeficiency syndrome	6.29e-05	0.000326	CcSEcCtD
Vandetanib—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	6.28e-05	0.000325	CcSEcCtD
Vandetanib—Headache—Lamivudine—acquired immunodeficiency syndrome	6.25e-05	0.000324	CcSEcCtD
Vandetanib—Nausea—Saquinavir—acquired immunodeficiency syndrome	6.21e-05	0.000322	CcSEcCtD
Vandetanib—Nausea—Lamivudine—acquired immunodeficiency syndrome	5.93e-05	0.000307	CcSEcCtD
Vandetanib—LYN—Immune System—CSF2—acquired immunodeficiency syndrome	1.44e-05	0.000186	CbGpPWpGaD
Vandetanib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.44e-05	0.000186	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.44e-05	0.000186	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.44e-05	0.000186	CbGpPWpGaD
Vandetanib—LCK—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	1.44e-05	0.000185	CbGpPWpGaD
Vandetanib—SRC—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	1.44e-05	0.000185	CbGpPWpGaD
Vandetanib—FYN—Immune System—CD40LG—acquired immunodeficiency syndrome	1.43e-05	0.000185	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CD8A—acquired immunodeficiency syndrome	1.43e-05	0.000185	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CSF2—acquired immunodeficiency syndrome	1.43e-05	0.000185	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—CD4—acquired immunodeficiency syndrome	1.43e-05	0.000185	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—IL2—acquired immunodeficiency syndrome	1.43e-05	0.000185	CbGpPWpGaD
Vandetanib—BLK—Immune System—IFNG—acquired immunodeficiency syndrome	1.43e-05	0.000184	CbGpPWpGaD
Vandetanib—FGR—Immune System—IFNG—acquired immunodeficiency syndrome	1.42e-05	0.000184	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.42e-05	0.000184	CbGpPWpGaD
Vandetanib—SRC—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	1.42e-05	0.000184	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.42e-05	0.000183	CbGpPWpGaD
Vandetanib—FYN—Immune System—CSF2—acquired immunodeficiency syndrome	1.42e-05	0.000183	CbGpPWpGaD
Vandetanib—FYN—Immune System—CD8A—acquired immunodeficiency syndrome	1.42e-05	0.000183	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HLA-B—acquired immunodeficiency syndrome	1.42e-05	0.000183	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.41e-05	0.000183	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—ALB—acquired immunodeficiency syndrome	1.41e-05	0.000182	CbGpPWpGaD
Vandetanib—SRC—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	1.41e-05	0.000182	CbGpPWpGaD
Vandetanib—SRC—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	1.4e-05	0.000181	CbGpPWpGaD
Vandetanib—ABCC1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.4e-05	0.000181	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.4e-05	0.000181	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.39e-05	0.00018	CbGpPWpGaD
Vandetanib—LYN—Immune System—HLA-B—acquired immunodeficiency syndrome	1.39e-05	0.000179	CbGpPWpGaD
Vandetanib—ALB—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	1.38e-05	0.000178	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HLA-B—acquired immunodeficiency syndrome	1.38e-05	0.000178	CbGpPWpGaD
Vandetanib—BLK—Immune System—CD4—acquired immunodeficiency syndrome	1.38e-05	0.000178	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.38e-05	0.000178	CbGpPWpGaD
Vandetanib—FGR—Immune System—CD4—acquired immunodeficiency syndrome	1.38e-05	0.000178	CbGpPWpGaD
Vandetanib—LYN—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	1.37e-05	0.000177	CbGpPWpGaD
Vandetanib—FYN—Immune System—HLA-B—acquired immunodeficiency syndrome	1.36e-05	0.000176	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.36e-05	0.000176	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.36e-05	0.000176	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.35e-05	0.000174	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.35e-05	0.000174	CbGpPWpGaD
Vandetanib—FYN—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	1.35e-05	0.000174	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—CSF2—acquired immunodeficiency syndrome	1.35e-05	0.000174	CbGpPWpGaD
Vandetanib—KDR—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.34e-05	0.000174	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.34e-05	0.000173	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.34e-05	0.000173	CbGpPWpGaD
Vandetanib—SRC—Immune System—IFNA1—acquired immunodeficiency syndrome	1.34e-05	0.000172	CbGpPWpGaD
Vandetanib—RIPK2—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.33e-05	0.000172	CbGpPWpGaD
Vandetanib—FYN—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.33e-05	0.000171	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.32e-05	0.000171	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—IL2—acquired immunodeficiency syndrome	1.32e-05	0.00017	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.32e-05	0.00017	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.31e-05	0.00017	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—IFNG—acquired immunodeficiency syndrome	1.31e-05	0.000169	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.3e-05	0.000168	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.3e-05	0.000168	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—ALB—acquired immunodeficiency syndrome	1.3e-05	0.000168	CbGpPWpGaD
Vandetanib—SRC—Immune System—CD79A—acquired immunodeficiency syndrome	1.3e-05	0.000167	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.29e-05	0.000167	CbGpPWpGaD
Vandetanib—SRC—Disease—CXCR4—acquired immunodeficiency syndrome	1.29e-05	0.000166	CbGpPWpGaD
Vandetanib—FGR—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.28e-05	0.000165	CbGpPWpGaD
Vandetanib—SRC—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	1.27e-05	0.000164	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.27e-05	0.000164	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.27e-05	0.000164	CbGpPWpGaD
Vandetanib—BLK—Immune System—IL2—acquired immunodeficiency syndrome	1.27e-05	0.000164	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.27e-05	0.000164	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.27e-05	0.000164	CbGpPWpGaD
Vandetanib—FGR—Immune System—IL2—acquired immunodeficiency syndrome	1.27e-05	0.000163	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—CD4—acquired immunodeficiency syndrome	1.26e-05	0.000163	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.25e-05	0.000161	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.24e-05	0.000161	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.24e-05	0.00016	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.24e-05	0.00016	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—CCR5—acquired immunodeficiency syndrome	1.24e-05	0.00016	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CD40LG—acquired immunodeficiency syndrome	1.24e-05	0.00016	CbGpPWpGaD
Vandetanib—ABCG2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.23e-05	0.000159	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.23e-05	0.000158	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CD8A—acquired immunodeficiency syndrome	1.23e-05	0.000158	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CSF2—acquired immunodeficiency syndrome	1.23e-05	0.000158	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.22e-05	0.000158	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.22e-05	0.000158	CbGpPWpGaD
Vandetanib—LYN—Axon guidance—IL6—acquired immunodeficiency syndrome	1.22e-05	0.000157	CbGpPWpGaD
Vandetanib—ABL1—Axon guidance—IL6—acquired immunodeficiency syndrome	1.21e-05	0.000157	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.21e-05	0.000156	CbGpPWpGaD
Vandetanib—VEGFA—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.21e-05	0.000156	CbGpPWpGaD
Vandetanib—FYN—Axon guidance—IL6—acquired immunodeficiency syndrome	1.2e-05	0.000155	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.2e-05	0.000155	CbGpPWpGaD
Vandetanib—FYN—Disease—CCR5—acquired immunodeficiency syndrome	1.2e-05	0.000155	CbGpPWpGaD
Vandetanib—LCK—Immune System—CD40LG—acquired immunodeficiency syndrome	1.19e-05	0.000154	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—IL2—acquired immunodeficiency syndrome	1.19e-05	0.000154	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.18e-05	0.000153	CbGpPWpGaD
Vandetanib—LCK—Immune System—CSF2—acquired immunodeficiency syndrome	1.18e-05	0.000152	CbGpPWpGaD
Vandetanib—LCK—Immune System—CD8A—acquired immunodeficiency syndrome	1.18e-05	0.000152	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HLA-B—acquired immunodeficiency syndrome	1.18e-05	0.000152	CbGpPWpGaD
Vandetanib—ERBB3—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.17e-05	0.000152	CbGpPWpGaD
Vandetanib—ERBB3—Disease—CD4—acquired immunodeficiency syndrome	1.17e-05	0.000151	CbGpPWpGaD
Vandetanib—YES1—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.17e-05	0.000151	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.16e-05	0.00015	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—IL2—acquired immunodeficiency syndrome	1.16e-05	0.00015	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.16e-05	0.00015	CbGpPWpGaD
Vandetanib—YES1—Immune System—IFNG—acquired immunodeficiency syndrome	1.15e-05	0.000148	CbGpPWpGaD
Vandetanib—EGFR—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.15e-05	0.000148	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.14e-05	0.000148	CbGpPWpGaD
Vandetanib—LCK—Immune System—HLA-B—acquired immunodeficiency syndrome	1.14e-05	0.000147	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.12e-05	0.000145	CbGpPWpGaD
Vandetanib—LCK—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	1.12e-05	0.000145	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.12e-05	0.000144	CbGpPWpGaD
Vandetanib—YES1—Immune System—CD4—acquired immunodeficiency syndrome	1.11e-05	0.000143	CbGpPWpGaD
Vandetanib—LCK—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.1e-05	0.000143	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	1.1e-05	0.000142	CbGpPWpGaD
Vandetanib—ABCC1—Disease—CCR5—acquired immunodeficiency syndrome	1.1e-05	0.000142	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.08e-05	0.00014	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—TNF—acquired immunodeficiency syndrome	1.08e-05	0.000139	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.08e-05	0.000139	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—TNF—acquired immunodeficiency syndrome	1.07e-05	0.000139	CbGpPWpGaD
Vandetanib—MKNK1—Disease—IL6—acquired immunodeficiency syndrome	1.07e-05	0.000138	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—TNF—acquired immunodeficiency syndrome	1.06e-05	0.000137	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.06e-05	0.000137	CbGpPWpGaD
Vandetanib—SRC—Immune System—CD40LG—acquired immunodeficiency syndrome	1.06e-05	0.000137	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.06e-05	0.000137	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.06e-05	0.000137	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—IL2—acquired immunodeficiency syndrome	1.05e-05	0.000136	CbGpPWpGaD
Vandetanib—SRC—Immune System—CD8A—acquired immunodeficiency syndrome	1.05e-05	0.000135	CbGpPWpGaD
Vandetanib—SRC—Immune System—CSF2—acquired immunodeficiency syndrome	1.05e-05	0.000135	CbGpPWpGaD
Vandetanib—EGFR—Axon guidance—IL6—acquired immunodeficiency syndrome	1.04e-05	0.000134	CbGpPWpGaD
Vandetanib—EGFR—Disease—CCR5—acquired immunodeficiency syndrome	1.03e-05	0.000134	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.03e-05	0.000133	CbGpPWpGaD
Vandetanib—YES1—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.03e-05	0.000133	CbGpPWpGaD
Vandetanib—YES1—Immune System—IL2—acquired immunodeficiency syndrome	1.02e-05	0.000132	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.02e-05	0.000132	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.02e-05	0.000132	CbGpPWpGaD
Vandetanib—SRC—Immune System—HLA-B—acquired immunodeficiency syndrome	1.01e-05	0.00013	CbGpPWpGaD
Vandetanib—LCK—Disease—CCR5—acquired immunodeficiency syndrome	9.97e-06	0.000129	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	9.9e-06	0.000128	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.84e-06	0.000127	CbGpPWpGaD
Vandetanib—SRC—Signaling by NGF—IL6—acquired immunodeficiency syndrome	9.78e-06	0.000126	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.66e-06	0.000125	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9.59e-06	0.000124	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.52e-06	0.000123	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.46e-06	0.000122	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	9.36e-06	0.000121	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.32e-06	0.00012	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.31e-06	0.00012	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.17e-06	0.000118	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—TNF—acquired immunodeficiency syndrome	9.17e-06	0.000118	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.02e-06	0.000116	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.02e-06	0.000116	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9e-06	0.000116	CbGpPWpGaD
Vandetanib—SRC—Axon guidance—IL6—acquired immunodeficiency syndrome	8.85e-06	0.000114	CbGpPWpGaD
Vandetanib—SRC—Disease—CCR5—acquired immunodeficiency syndrome	8.83e-06	0.000114	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IFNG—acquired immunodeficiency syndrome	8.75e-06	0.000113	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.7e-06	0.000112	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—IL6—acquired immunodeficiency syndrome	8.7e-06	0.000112	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—IL6—acquired immunodeficiency syndrome	8.66e-06	0.000112	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—IL6—acquired immunodeficiency syndrome	8.58e-06	0.000111	CbGpPWpGaD
Vandetanib—LYN—Immune System—IFNG—acquired immunodeficiency syndrome	8.57e-06	0.000111	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—IL6—acquired immunodeficiency syndrome	8.57e-06	0.000111	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.53e-06	0.00011	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IFNG—acquired immunodeficiency syndrome	8.53e-06	0.00011	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.52e-06	0.00011	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—CD4—acquired immunodeficiency syndrome	8.45e-06	0.000109	CbGpPWpGaD
Vandetanib—FYN—Immune System—IFNG—acquired immunodeficiency syndrome	8.44e-06	0.000109	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.39e-06	0.000108	CbGpPWpGaD
Vandetanib—LYN—Immune System—CD4—acquired immunodeficiency syndrome	8.28e-06	0.000107	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CD4—acquired immunodeficiency syndrome	8.24e-06	0.000106	CbGpPWpGaD
Vandetanib—FYN—Immune System—CD4—acquired immunodeficiency syndrome	8.15e-06	0.000105	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.04e-06	0.000104	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.92e-06	0.000102	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—IL6—acquired immunodeficiency syndrome	7.85e-06	0.000101	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—TNF—acquired immunodeficiency syndrome	7.82e-06	0.000101	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—CD4—acquired immunodeficiency syndrome	7.8e-06	0.000101	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.8e-06	0.000101	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL2—acquired immunodeficiency syndrome	7.78e-06	0.0001	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—IL6—acquired immunodeficiency syndrome	7.76e-06	0.0001	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.75e-06	0.0001	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—IL6—acquired immunodeficiency syndrome	7.68e-06	9.92e-05	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—IL6—acquired immunodeficiency syndrome	7.65e-06	9.87e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.64e-06	9.86e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL2—acquired immunodeficiency syndrome	7.61e-06	9.83e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.6e-06	9.82e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL2—acquired immunodeficiency syndrome	7.58e-06	9.78e-05	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—IL6—acquired immunodeficiency syndrome	7.57e-06	9.77e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—CD4—acquired immunodeficiency syndrome	7.52e-06	9.71e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.52e-06	9.71e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL2—acquired immunodeficiency syndrome	7.5e-06	9.68e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—IL6—acquired immunodeficiency syndrome	7.46e-06	9.63e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.46e-06	9.63e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—IL6—acquired immunodeficiency syndrome	7.44e-06	9.6e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—IL6—acquired immunodeficiency syndrome	7.4e-06	9.55e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IFNG—acquired immunodeficiency syndrome	7.29e-06	9.41e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.25e-06	9.36e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—IL2—acquired immunodeficiency syndrome	7.12e-06	9.19e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.09e-06	9.15e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CD4—acquired immunodeficiency syndrome	7.04e-06	9.09e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—IFNG—acquired immunodeficiency syndrome	7.02e-06	9.07e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.98e-06	9.02e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—CD4—acquired immunodeficiency syndrome	6.89e-06	8.9e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.86e-06	8.86e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—IL6—acquired immunodeficiency syndrome	6.84e-06	8.83e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.84e-06	8.82e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—CD4—acquired immunodeficiency syndrome	6.78e-06	8.76e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.76e-06	8.73e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.6e-06	8.52e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—ALB—acquired immunodeficiency syndrome	6.55e-06	8.46e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—IL6—acquired immunodeficiency syndrome	6.54e-06	8.44e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—CD4—acquired immunodeficiency syndrome	6.5e-06	8.39e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL2—acquired immunodeficiency syndrome	6.48e-06	8.36e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—IL6—acquired immunodeficiency syndrome	6.31e-06	8.15e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—IL6—acquired immunodeficiency syndrome	6.31e-06	8.15e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—IL6—acquired immunodeficiency syndrome	6.3e-06	8.13e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—CD4—acquired immunodeficiency syndrome	6.26e-06	8.09e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL2—acquired immunodeficiency syndrome	6.24e-06	8.06e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IFNG—acquired immunodeficiency syndrome	6.22e-06	8.03e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.18e-06	7.98e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CD4—acquired immunodeficiency syndrome	6.01e-06	7.75e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—IL6—acquired immunodeficiency syndrome	6e-06	7.75e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—ALB—acquired immunodeficiency syndrome	5.77e-06	7.44e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—IL6—acquired immunodeficiency syndrome	5.58e-06	7.2e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—CD4—acquired immunodeficiency syndrome	5.54e-06	7.16e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL2—acquired immunodeficiency syndrome	5.53e-06	7.13e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.03e-06	6.49e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.01e-06	6.47e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.92e-06	6.36e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.85e-06	6.26e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.59e-06	5.92e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL6—acquired immunodeficiency syndrome	4.57e-06	5.9e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL6—acquired immunodeficiency syndrome	4.48e-06	5.78e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.47e-06	5.77e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL6—acquired immunodeficiency syndrome	4.45e-06	5.75e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.42e-06	5.71e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL6—acquired immunodeficiency syndrome	4.41e-06	5.69e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—IL6—acquired immunodeficiency syndrome	4.22e-06	5.45e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.19e-06	5.41e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.17e-06	5.38e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—IL6—acquired immunodeficiency syndrome	4.07e-06	5.25e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.04e-06	5.21e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.02e-06	5.19e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.88e-06	5.01e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL6—acquired immunodeficiency syndrome	3.81e-06	4.91e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—IL6—acquired immunodeficiency syndrome	3.73e-06	4.81e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL6—acquired immunodeficiency syndrome	3.67e-06	4.74e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.57e-06	4.61e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—IL6—acquired immunodeficiency syndrome	3.51e-06	4.54e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—IL6—acquired immunodeficiency syndrome	3.39e-06	4.37e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL6—acquired immunodeficiency syndrome	3.25e-06	4.19e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—IL6—acquired immunodeficiency syndrome	3e-06	3.87e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.96e-06	3.82e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.89e-06	3.74e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.85e-06	3.68e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.46e-06	3.18e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.37e-06	3.06e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.1e-06	2.71e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	1.92e-06	2.48e-05	CbGpPWpGaD
